The FDA has approved an expanded indication for Fluarix Quadrivalent (influenza vaccine) for persons aged 6 months and older.

Indications: Fluarix Quadrivalent is a vaccine for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.

Dosage and administration: Providers should use the same dose of Fluarix Quadrivalent (15 ug of hemagglutinin per virus strain in 0.5 mL) to cover all eligible persons aged 6 months and older.

Adverse reactions:

• In children aged 6 through 35 months, the most common solicited adverse reactions were pain and redness; the most common systemic adverse reactions were irritability, loss of appetite, and drowsiness.
• In children aged 3 through 17 years, solicited local adverse reactions were pain, redness, and swelling.
• In children aged 3 through 5 years, the most common systemic adverse reactions were drowsiness, irritability, and loss of appetite.
• In children aged 6 through 17 years, the most common systemic adverse reactions were fatigue, muscle aches, headache, arthralgia, and gastrointestinal symptoms.